Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pediatrix Medical GroupFRA:PDC -0.88%55 3-Year EBITDA Growth Rate is 20.00% as of Jun. 2026, which is 63% above its 10-year median of 12.25. GuruFocus rates FRA:PDC with a GF Score™ of 55/100 and a GF Value™ of €11.37. The stock has 8 warning signs investors should review. Among 524 Healthcare Providers & Services companies, Pediatrix Medical Group ranks better than 66.03% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Pediatrix Medical Group was 68.70% per year. The lowest was -40.80% per year. And the median was 12.25% per year.
Pediatrix Medical Group (FRA:PDC) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Pediatrix Medical Group 3-Year EBITDA Growth Rate Related Terms
FRA:PDC vs ADUS, AVAH, SGRY: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Pediatrix Medical Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pediatrix Medical Group 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Pediatrix Medical Group's 3-Year EBITDA Growth Rate falls into.
Pediatrix Medical Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.00% mean?
Pediatrix Medical Group (FRA:PDC) has a 3-Year EBITDA Growth Rate of 20.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pediatrix Medical Group and its competitors. This is 63% above median its historical median of 12.25. According to the industry distribution chart, Pediatrix Medical Group ranks #178 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 34%.
Is Pediatrix Medical Group's 3-Year EBITDA Growth Rate too high?
Pediatrix Medical Group's current 3-Year EBITDA Growth Rate of 20.00% is 63% above median its 10-year median of 12.25. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.25. Pediatrix Medical Group's value of 20.00% is 95.1% above this industry median. Based on the distribution chart, Pediatrix Medical Group ranks #178 out of 524 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pediatrix Medical Group has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's 3-Year EBITDA Growth Rate compare to ADUS and AVAH?
According to the Healthcare Providers & Services industry distribution chart, Pediatrix Medical Group ranks #178 out of 524 companies for 3-Year EBITDA Growth Rate. This puts Pediatrix Medical Group in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.25. Pediatrix Medical Group's value of 20.00% is 95.1% above this benchmark. While the company's 10-year median is 12.25 vs. the industry median of 10.25, Pediatrix Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.25, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pediatrix Medical Group's current 3-Year EBITDA Growth Rate of 20.00% is 95.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pediatrix Medical Group and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pediatrix Medical Group's current 3-Year EBITDA Growth Rate is 20.00%, which is 63% above median its own 10-year median of 12.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Pediatrix Medical Group (FRA:PDC) has a current 3-Year EBITDA Growth Rate of 20.00%. The stock's GF Value™ is €11.37, compared to a current price of €22.40 — trading 97% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.00%, which is 63% above median its 10-year median of 12.25 and 95.1% above the Healthcare Providers & Services industry median of 10.25. Pediatrix Medical Group's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current 3-Year EBITDA Growth Rate is 20.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?
Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued.
The current stock price of €22.40 is trading 97% above its estimated GF Value™ of €11.37.
Key valuation signals for FRA:PDC:
3-Year EBITDA Growth Rate: 20.00% (63% above median its 10-year median of 12.25)
GF Value™: €11.37 vs. price of €22.40 (97% above fair value)
Industry Position: 95.1% above the Healthcare Providers & Services median (#178 of 524)
No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
55GF Score
Get the complete analysis for FRA:PDC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDC has been successfully added to your 
